Total trials
241
Active
36
Phase 3
6
Total enrollment
76,161
Pipeline matrix
Showing 4 of 4 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Simvastatin | — | — | — | — | — | 1 | |
| Simvastatin 10 mg | — | — | — | — | — | 1 | |
| Simvastatin Placebo | — | — | — | — | — | 1 | |
| osteoimplant | — | — | — | — | — | 1 |
Next readouts
- 2025-01-07
- 2025-12-31
Top conditions
- Fibromyalgia16
- Breast Cancer7
- Obesity6
- Healthy6
- Stroke5
- Chronic Obstructive Pulmonary Disease5
- COPD Exacerbation4
- Quality of Life4
Frequently asked questions about Universidad de Granada
- How many clinical trials does Universidad de Granada have on ClinicalTrials.gov?
- Universidad de Granada is listed as the lead sponsor on 241 clinical trials in ClinicalTrials.gov, 36 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Universidad de Granada's trials are in Phase 3?
- 6 of Universidad de Granada's trials are in Phase 3, spread across 4 active drug programs.
- What therapeutic areas does Universidad de Granada focus on?
- Universidad de Granada's most-studied conditions on ClinicalTrials.gov are Fibromyalgia, Breast Cancer, Obesity, Healthy, Stroke.
- When are Universidad de Granada's next clinical trial readouts?
- Universidad de Granada has 2 upcoming primary-completion readouts tracked here; the soonest is “Topic Simvastatin for Bone Regeneration”, expected around 2025-01-07.